Sex differences in clinical trials of ALRV5XR treatment of androgenetic alopecia and telogen effluvium.

ABSTRACT:

Introduction

ALRV5XR treatment of androgenetic alopecia (AGA) and telogen effluvium (TE) has early evidence of regenerating a normal scalp hair phenotype in both sexes.

Design

We performed two 24-week double-blinded placebo-controlled comparison trials, one in each sex, on the ALRV5XR treatment effect on hair regeneration, in AGA and TE, in 92 AGA subjects (24 also had TE). Forty-six women (age 24-64 years) and 46 men (age 22-63 years) were randomized 1:1 to either ALRV5XR or placebo regimens (one b.i.d. oral capsule and daily administration of shampoo, conditioner, and follicle serum).

Evaluation

Primary outcomes: Absolute and relative changes in terminal hair (TH) density. Secondary outcomes: Response rate, changes in vellus hair (VH) density, TH/VH ra

SUBMITTER: Feldman PR 

PROVIDER: S-EPMC9421616 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature